2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thromboembolism, Thrombotic Disorders, VWD, Genetic Disorders, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5564 a novel anchor-based continuous response assessment of spleen and symptom improvement from the phase 3 BOREAS study of navtemadlin in relapsed or refractory (R/R) myelofibrosis (MF)

Pankit Vachhani, MD, Haifa Kathrin Al-Ali, MD2, Florian Heidel3, Raajit K. Rampal, MD, PhD4, Jean-Jacques Kiladjian5, Alessandro Maria Vannucchi6, Zhuying Huang7, Hope Qamoos, NP8, Jesse McGreivy9, Wayne Rothbaum, MS10, Srdan Verstovsek, MD11, John O. Mascarenhas, MD12
1 The University of Alabama at Birmingham, Birmingham, Alabama, United States
2 University Hospital of Halle, Halle, Germany
3 Hematology, Hemostasis, Oncology, and Cell Therapy, Hannover Medical School, Hannover, Germany
4 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Hopital Saint-Louis, Paris, France
6 Center for Research and Innovation of Myeloproliferative Neoplasms University of Florence, Florence, Italy
7 Kartos Therapeutics, Inc., Redwood City, California, United States
8 Kartos Therapeutics, Inc., Redwood City, California, United States
9 Kartos Therapeutics, Inc., Redwood City, California, United States
10 Kartos Therapeutics, Inc., Redwood City, California, United States
11 Kartos Therapeutics, Inc., Redwood City, California, United States
12 Icahn School of Medicine at Mount Sinai, New York, New York, United States

Introduction: In MF trials, efficacy is typically assessed using the binary endpoints (EPs) spleen volume reduction ≥35% (SVR35) and total symptom score reduction ≥50% (TSS50) at Week 24 (Wk24). Established during early JAK inhibitor (JAKi) development in JAKi-naïve MF, binary EPs may not fully capture clinically meaningful benefit over time in patients (pts) with more advanced JAKi-refractory disease. Alternate methods to evaluate clinical benefit, such as continuous measures of spleen and symptom improvement, may provide a more comprehensive and context-specific assessment of meaningful treatment effect. BOREAS is a global, open-label Phase 3 study demonstrating clinically relevant improvements in SVR35 and TSS50 with the oral MDM2 inhibitor navtemadlin (NVTM) vs best available therapy (BAT) in JAKi-R/R MF (Mascarenhas 2024). This exploratory analysis evaluated whether continuous measures of spleen and symptom improvement, interpreted using clinically meaningful anchors, more comprehensively captured treatment benefit in JAKi-R/R MF.

Methods: BOREAS (NCT03662126) enrolled adult pts with TP53 wild-type intermediate-/high-risk primary or secondary JAKi-R/R MF. JAKi-intolerant pts and suboptimal responders were excluded. Pts were randomized 2:1 to NVTM 240 mg once daily on days 1–7 of 28-day cycles (n=123) or BAT (n=60). The primary EP was SVR35 at Wk24 by blinded MRI/CT central review, the key secondary EP was TSS50 at Wk24 by MFSAF v4.0. SVR was assessed every 12 weeks, palpable spleen length reduction (SLR) every 4 weeks, and TSS and Patient Global Impression of Change (PGIC) every cycle. Enrollment closed before full accrual (183/282 planned) due to resource allocation by the sponsor, resulting in underpowering of the primary analysis. Absolute mean change in SV and TSS from baseline to Wk24 were evaluated using anchor-based meaningful-change analysis. For SV, SLR ≥50% served as the clinically meaningful improvement anchor. For symptoms, PGIC (range, −3 to +3) served as the historical anchor. Empirical cumulative distribution function (eCDF) analyses were used to derive clinically meaningful change thresholds for continuous measures of SV and symptom improvement. Treatment effects were estimated using ANCOVA adjusted for MF subtype and baseline SV/TSS. Multiple imputation (MI) was used for missing Wk24 data, with observed-case and carry-forward sensitivity analyses. Data cutoff was Sept 30, 2024 (primary analysis).  

Results: In the primary analysis, conventional EPs showed greater benefit with NVTM vs BAT: SVR35 was achieved in 15% vs 5% (P=0.082), SVR25 in 27% vs 10% (P=0.012), and TSS50 in 24% vs 12% (P=0.051), respectively. Using absolute mean change, least-squares mean (LSM) SVR at Wk24 with MI was −391 cm³ for NVTM and −140 cm³ for BAT (−251 cm³; P=0.022), consistent with observed-case changes (−458 vs −198 cm³; P=0.032). SVR correlated with SLR (r=0.367; P<0.001), supporting SLR as a suitable meaningful-change anchor for continuous SVR. In the eCDF analysis, median absolute SVR was −618 cm³ for pts with ≥50% SLR, establishing a meaningful change SVR threshold in JAKi-R/R MF. eCDF by treatment arm showed clear curve separation at and beyond the clinically meaningful change threshold. At Wk24, 23% (28/123) of pts receiving NVTM vs 10% (6/60) receiving BAT achieved ≥618 cm³ SVR (P=0.043). 

For symptoms, LSM TSS change at Wk24 with MI was −5.3 for NVTM vs −0.1 for BAT (−5.2 points; P=0.010), consistent with observed-case changes (−7.3 vs −3.3; −4.0 points; P=0.073). TSS change correlated with PGIC (r=−0.27), supporting PGIC as a suitable meaningful change anchor for continuous TSS. For pts reporting PGIC improvement, median absolute TSS change was −6.0, establishing a meaningful change symptom improvement threshold. eCDF by treatment arm showed clear curve separation at and beyond the clinically meaningful change threshold. At Wk24, 33% (41/123) of pts receiving NVTM vs 17% (10/60) receiving BAT achieved ≥6-point reduction in TSS (P=0.022).

Conclusions
: In this exploratory analysis of BOREAS, clinically meaningful treatment benefit favored NVTM over BAT and extended beyond conventional SVR35 and TSS50 responder classifications. Because SVR35 and TSS50 were established in predominantly JAKi-naïve MF populations, setting-specific anchor-based analyses, applied to continuous measures of SVR and symptom improvement, may capture a more comprehensive assessment of clinically meaningful benefit in pts with JAKi-R/R MF.

Pankit Vachhani, MD: Novartis - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); Blueprint Medicines Corporation, a wholly owned subsidiary of Sanofi - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony); Kartos - Consultancy (Includes expert testimony); Silence Therapeutics - Consultancy (Includes expert testimony); Prelude Therapeutics - Consultancy (Includes expert testimony); DISC Medicine - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Cogent Biosciences - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Merck & Co., Inc - Consultancy (Includes expert testimony)